ChemoMetec A/S affirmed earnings guidance for the fiscal year 2022/2023. For the year, based on developments in the third quarter of 2022/23, guidance for financial year 2022/23, as announced in connection with the release of the interim report for 2022/23 on 8 February 2023, is maintained. Accordingly, revenue for 2022/23 is expected in the range of DKK 430 million - DKK 460 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
315.2 DKK | -1.07% |
|
-5.06% | -18.76% |
May. 27 | Denmark's ChemoMetec Appoints New CFO | MT |
May. 24 | ChemoMetec A/S Announces CFO Changes | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.76% | 787M | |
+75.69% | 12.57B | |
-25.35% | 7.28B | |
+15.77% | 7.2B | |
+14.52% | 5.47B | |
-18.50% | 4.73B | |
+14.91% | 4.09B | |
-23.67% | 3.78B | |
+42.93% | 2.3B | |
-0.37% | 2.03B |
- Stock Market
- Equities
- CHEMM Stock
- News ChemoMetec A/S
- ChemoMetec A/S Affirms Earnings Guidance for the Fiscal Year 2022/2023